In murine PDAC, IL-33 activates TILC2s to secrete CCL5, which subsequently recruits CD103+ DCs to TME; DCs then activate CD8+ T cells through antigen presentation, thereby enhancing the anti-tumor immunity (79). This evidence concerns the gene IL33 and neoplasm.